Ducommun Incorporated Issues Restatement of Financial Statements for 2024 and 2025: Significant Overstatements Disclosed

Key Highlights

• Restatement Announced: Ducommun Incorporated (“Ducommun” or “the Company”) has determined that its previously issued audited and unaudited financial statements for fiscal years 2024 and 2025, including quarterly reports, can no longer be relied upon.
• Material Overstatements Identified: Management identified significant errors during the preparation of the Q1 2026 consolidated financial statements, leading to a restatement of operating income, net income, and (loss) earnings per share for the affected periods.
• Restatement Process: The Company intends to file an amended Annual Report on Form 10-K for the year ended December 31, 2025, which will include restated financials for all affected periods.
• Audit Committee and Independent Auditor Involvement: The Audit Committee, Board of Directors, and independent registered public accounting firm PricewaterhouseCoopers LLP (“PwC”) concurred with management’s findings.
• Internal Controls: The Company’s Internal Control over Financial Reporting as of December 31, 2025, should no longer be relied upon. A remediation plan is being developed.
• Stock-Based Compensation Impact: Due to revised accounting treatment, Q1 2026 stock-based compensation expense is expected to be \$5.0-6.0 million higher than prior expectations, but the full-year 2026 estimate remains unchanged.
• No Impact on Debt Covenants: The restatement does not affect compliance with debt covenants or cash flow figures for the affected periods.

Detailed Overview of the Restatement

While preparing its Q1 2026 financials, Ducommun management discovered an error that led to the overstatement of key financial metrics in both its annual and quarterly statements for the periods ending December 31, 2024 and December 31, 2025. The following documents are impacted:

• Audited consolidated financial statements and associated audit report for years ended December 31, 2024 and 2025.
• Unaudited condensed consolidated financial statements for quarters ended June 29, 2024; September 28, 2024; March 29, 2025; June 28, 2025; and September 27, 2025.

Collectively, these are referred to as the “Affected Periods.” All impacted filings will be amended, and the restated numbers will be included in the upcoming amended 10-K.

Quantified Impact of Restatement

• Operating Income (Loss):
  • Overstated by an estimated \$10.0 million for FY 2024
  • Overstated by an estimated \$3.4 million for FY 2025
• Net Income (Loss):
  • Overstated by an estimated \$9.8 million for FY 2024
  • Overstated by an estimated \$3.4 million for FY 2025
• Diluted (Loss) Earnings Per Share:
  • Overstated by approximately \$0.65 for FY 2024
  • Overstated by approximately \$0.22 for FY 2025
• Adjusted EBITDA:
  • Overstated by \$0.9 million for FY 2024
  • Understated by \$0.5 million for FY 2025
• Unaffected Metrics:
  • Gross margin for 2024 and 2025 remains unchanged
  • Cash flow from operations and free cash flow for 2024 and 2025 remain unchanged

Internal Controls and Audit Report

The identified errors have also led management and the Audit Committee to conclude that the Company’s internal controls over financial reporting as of December 31, 2025, were ineffective. PwC’s audit reports on both the consolidated financial statements and internal controls as of December 31, 2025, should no longer be relied upon. A remediation plan will be disclosed in the amended 10-K/A, targeted for filing on or before May 8, 2026.

Stock-Based Compensation: Future Impact

Due to the revised accounting for stock-based compensation, Ducommun expects to incur an additional \$5.0–\$6.0 million in stock-based compensation expense in Q1 2026 relative to previous guidance. However, the full-year 2026 guidance for this expense is not expected to change.

Management and Auditor Assurance

Importantly, the Company states that these issues did not involve any intentional misconduct by management or employees. The financial restatements are based on preliminary data and may be further updated once the internal review and audit processes are finalized.

Non-GAAP Measures and Reconciliations

The Company has provided detailed reconciliations for GAAP and non-GAAP measures, including Adjusted EBITDA and non-GAAP diluted earnings per share. These are intended to offer investors transparency and facilitate comparisons, but investors are cautioned that non-GAAP metrics may not be directly comparable to those of other companies.

What Shareholders and Investors Need to Know

• Restatement of financials is a significant event and often leads to increased scrutiny from the market, regulators, and investors.
• The magnitude of the overstatements (\$9.8M in net income for 2024, \$3.4M for 2025) is material and may impact investor confidence and potentially the share price.
• The effectiveness of internal controls is in question, increasing the risk profile of the Company until remediation is completed.
• PwC’s audit reports for the affected periods are no longer reliable, which may impact lender and investor trust.
• The Company expects to complete its restatement process and issue amended filings by May 8, 2026. Investors should closely monitor these developments.
• While stock-based compensation expense will spike in Q1 2026, no change is expected for the full year, which may partially reassure investors.
• No impact to cash flows or debt covenants has been identified, reducing concerns about liquidity or default risk.

Potential Market Impact

Restatements of this magnitude are typically considered material events and can negatively affect share prices due to concerns about earnings quality, management oversight, and internal controls. Investors should be prepared for potential volatility in Ducommun’s stock (DCO: NYSE) as the market digests this news and awaits further disclosures.

Forward-Looking Statements

This article contains forward-looking statements based on management’s current expectations. Actual results may differ materially due to various risk factors, including but not limited to, the outcome of the restatement process, additional findings during the review, and market reactions.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors are urged to perform their own due diligence and consult with their financial advisors before making any investment decisions. The author and publisher are not liable for any actions taken based on the information provided herein.

View DUCOMMUN INC /DE/ Historical chart here